

*File Copy***WEST**[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)**Search Results -**

Terms	Documents
L7 and (N-terminal and fibrin binding domain)	264

**Database:**

US Patents Full-Text Database

JPO Abstracts Database

EPO Abstracts Database

Derwent World Patents Index

IBM Technical Disclosure Bulletins

**Refine Search:**

L7 and (N-terminal and fibrin binding domain)

[Clear](#)**Search History****Today's Date: 12/31/2000**

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT	L7 and (N-terminal and fibrin binding domain)	264	<a href="#">L10</a>
USPT	L6 and (N-terminal and fibrin binding domain)	458	<a href="#">L9</a>
USPT	L6 and fibrin containing substance	1124798	<a href="#">L8</a>
USPT	L6 and (thrombus or atherosclerotic plaque)	272	<a href="#">L7</a>
USPT	L4 and fibrin	498	<a href="#">L6</a>
USPT	L4 and (L1 or fibrin)	2193	<a href="#">L5</a>
USPT	L1 and (marker or image or isotope or label)	2193	<a href="#">L4</a>
USPT	L2 not L1	174782	<a href="#">L3</a>
USPT	fibrin binding domain\$	178109	<a href="#">L2</a>
USPT	fibronectin\$	3975	<a href="#">L1</a>

=> d his

*File Copy*

(FILE 'HOME' ENTERED AT 18:06:32 ON 31 DEC 2000)

FILE 'BIOSIS, EMBASE, MEDLINE, SCISEARCH, LIFESCI, CAPLUS' ENTERED AT  
18:07:49 ON 31 DEC 2000

L1 96041 S FIBRONECTIN  
L2 31 S L1 AND (N-TERMINAL AND FIBRIN BINDING DOMAIN)  
L3 3979 S L1 AND (MARKER OR IMAGE OR ISOTOPE OR LABEL)  
L4 2707 S L1 AND FIBRIN  
L5 31 S L4 AND (N-TERMINAL AND FIBRIN BINDING DOMAIN)  
L6 118 S L4 AND (THROMBUS OR ATHEROSCLEROTIC PLAQUE)  
L7 2 S L5 AND L6

FILE 'BIOSIS, EMBASE, MEDLINE, SCISEARCH, LIFESCI, CAPLUS' ENTERED AT  
18:26:10 ON 31 DEC 2000

L8 96041 S FIBRONECTIN  
L9 84300 S FIBRIN  
L10 17 S L9 AND (N-TERMINAL FIBRIN BINDING DOMAIN)  
L11 1917 S L9 AND (MARKER OR IMAGE OR ISOTOPE OR LABEL)  
L12 927 DUP REM L11 (990 DUPLICATES REMOVED)  
L13 116 S L12 AND (THROMBUS OR ATHEROSCLEROTIC PLAQUE)  
L14 0 S L12 AND (N-TERMINAL FIBRIN BINDING DOMAIN)  
L15 0 S L10 AND L13  
L16 0 S L2 AND L12  
L17 0 S L2 AND L13

*STN  
Search Strategy*

09-047,661 8/11/00

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1600RXM

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Sep 29 The Philippines Inventory of Chemicals and Chemical  
Substances (PICCS) has been added to CHEMLIST  
NEWS 3 Oct 27 New Extraction Code PAX now available in Derwent  
Files  
NEWS 4 Oct 27 SET ABBREVIATIONS and SET PLURALS extended in  
Derwent World Patents Index files  
NEWS 5 Oct 27 Patent Assignee Code Dictionary now available  
in Derwent Patent Files  
NEWS 6 Oct 27 Plasdoc Key Serials Dictionary and Echoing added to  
Derwent Subscriber Files WPIDS and WPIX  
NEWS 7 Nov 29 Derwent announces further increase in updates for DWPI  
NEWS 8 Dec 5 French Multi-Disciplinary Database PASCAL Now on STN  
NEWS 9 Dec 5 Trademarks on STN - New DEMAS and EUMAS Files  
NEWS 10 Dec 15 2001 STN Pricing  
NEWS 11 Dec 17 Merged CEABA-VTB for chemical engineering and  
biotechnology  
NEWS 12 Dec 17 Corrosion Abstracts on STN  
NEWS 13 Dec 17 SYNTHLINE from Prous Science now available on STN  
NEWS 14 Dec 17 The CA Lexicon available in the CAPLUS and CA files

NEWS EXPRESS FREE UPGRADE 5.0DP1 FOR STN EXPRESS 5.0 WITH DISCOVER!  
(WINDOWS) NOW AVAILABLE

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

\*CFR - Code of Federal Regulations 1997 - present

\*CHEMCATS - CHEMICAL CATALOGS ONLINE 1993-1997

\* The files listed above are temporarily unavailable.

FILE 'HOME' ENTERED AT 18:06:32 ON 31 DEC 2000

=> File biosis, embase, medline, scisearch, lifesci, caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.30

0.30

FILE 'BIOSIS' ENTERED AT 18:07:49 ON 31 DEC 2000  
COPYRIGHT (C) 2000 BIOSIS(R)

FILE 'EMBASE' ENTERED AT 18:07:49 ON 31 DEC 2000  
COPYRIGHT (C) 2000 Elsevier Science B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 18:07:49 ON 31 DEC 2000

FILE 'SCISEARCH' ENTERED AT 18:07:49 ON 31 DEC 2000  
COPYRIGHT (C) 2000 Institute for Scientific Information (ISI) (R)

FILE 'LIFESCI' ENTERED AT 18:07:49 ON 31 DEC 2000  
COPYRIGHT (C) 2000 Cambridge Scientific Abstracts (CSA)

FILE 'CAPLUS' ENTERED AT 18:07:49 ON 31 DEC 2000  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

=> s fibronectin

=> s fibronectin

L1 96041 FIBRONECTIN

=> s L1 and (N-terminal and fibrin binding domain)

L2 31 L1 AND (N-TERMINAL AND FIBRIN BINDING DOMAIN)

=> s L1 and (marker or image or isotope or label)

L3 3979 L1 AND (MARKER OR IMAGE OR ISOTOPE OR LABEL)

=> s L1 and fibrin

L4 2707 L1 AND FIBRIN

=> s L4 and (N-terminal and fibrin binding domain)

L5 31 L4 AND (N-TERMINAL AND FIBRIN BINDING DOMAIN)

=> s L4 and(thrombus or atherosclerotic plaque)

L6 118 L4 AND(THROMBUS OR ATHEROSCLEROTIC PLAQUE)

=> s L5 and L6

L7 2 L5 AND L6

=> d his

(FILE 'HOME' ENTERED AT 18:06:32 ON 31 DEC 2000)

FILE 'BIOSIS, EMBASE, MEDLINE, SCISEARCH, LIFESCI, CAPLUS' ENTERED AT  
18:07:49 ON 31 DEC 2000

L1 96041 S FIBRONECTIN

L2 31 S L1 AND (N-TERMINAL AND FIBRIN BINDING DOMAIN)

L3 3979 S L1 AND (MARKER OR IMAGE OR ISOTOPE OR LABEL)

L4 2707 S L1 AND FIBRIN  
L5 31 S L4 AND (N-TERMINAL AND FIBRIN BINDING DOMAIN)  
L6 118 S L4 AND (THROMBUS OR ATHEROSCLEROTIC PLAQUE)  
L7 2 S L5 AND L6

=> d L7 1-2 bib kwic

L7 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2000 ACS  
AN 1997:277041 CAPLUS  
DN 127:31973

TI Recombinant polypeptides derived from the **fibrin binding domain of fibronectin** are potential agents for the imaging of blood clots

AU Ezov, N.; Nimrod, A.; Parizada, B.; Werber, M. M.; Goldlust, A.; Greenstein, L. A.; Vogel, T.; Drizlich, N.; Levanon, A.; Reich, S.; Gorecki, M.; Panet, Amos

CS Bio-Technology General, Rehovot, 76326, Israel

SO Thromb. Haemostasis (1997), 77(4), 796-803

CODEN: THHADQ; ISSN: 0340-6245

PB Schattauer

DT Journal

LA English

TI Recombinant polypeptides derived from the **fibrin binding domain of fibronectin** are potential agents for the imaging of blood clots

AB **Thrombus** formation in the circulation is accompanied by covalent linkage of **fibronectin** (FN) through transglutamination of GLN-3 in the **fibrin binding N-terminal domain** (FBD) of FN. This phenomenon was exploited for **thrombus** detection by the employment of radioactively-labeled recombinant polypeptide mols. derived from the 5-finger FBD of human FN. Three recombinant FBD polypeptides, 12 kDa ("2 fingers"), 18.5 kDa ("3 fingers"), and 31 kDa FBD ("5 fingers"), were prepd. and compared to native FN-derived 31 kDa-FBD with respect to their ability to attach to **fibrin** clots in vitro and in vivo. The accessibility of Gln-3 in these mols. was demonstrated by the incorporation of stoichiometric amts. of 14C-putrescine in the presence of plasma transglutaminase.

Competitive

binding expts. to **fibrin** have indicated that, although the binding affinities of the FBD mols. are lower than that of FN,

substantial

covalent linkage was obtained in the presence of transglutaminase, and in the presence of excess FN or heparin. The biol. clearance rates of labeled FBD mols. in rats and rabbits were much higher than those of FN and fibrinogen. The 12 kDa FBD exhibited the highest rate of clearance. The potential of the 12 kDa and 31 kDa FBDs as imaging agents was examd. in a stainless steel coil-induced **thrombus** model in rats and in a jugular vein **thrombus** model in rabbits. At 24 h, clot-to-blood ratios ranged between 10-22 for [125I]-12 kDa FBD and 40-60 for [111In]-12 kDa FBD. In the rat model, heparin did not inhibit the uptake of FBD.

ST **fibronectin fibrin fibrinogen thrombus**

IT Fibrins

RL: BAC (Biological activity or effector, except adverse); PRP (Properties); BIOL (Biological study)

(competitive inhibition of biotinylated r12 kDa **fibrin binding domain** binding to **fibrin**)

IT **Thrombus**

(**fibrin binding N-terminal domain** of **fibronectin** for **thrombus** detection)

IT Proteins (specific proteins and subclasses)

RL: BAC (Biological activity or effector, except adverse); BOC

(Biological

occurrence); BIOL (Biological study); OCCU (Occurrence)

(**fibronectin-binding**, 12 kDa, 18.5 kDa, 31 kDa polypeptides;

**fibrin binding N-terminal domain of fibronectin for thrombus detection)**

IT Fibronectins  
 RL: BAC (Biological activity or effector, except adverse); BOC  
 (Biological occurrence); BIOL (Biological study); OCCU (Occurrence)  
 (role of **thrombus** formation)

IT 80146-85-6, Transglutaminase  
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)  
 (competitive inhibition of biotinylated r12 kDa **fibrin binding domain** binding to **fibrin**)

IT 9005-49-6, Heparin, biological studies  
 RL: BAC (Biological activity or effector, except adverse); BIOL  
 (Biological study)  
 (effect of heparin on the binding of 12 kDa **fibrin binding N-terminal domain of fibronectin** to blood clots)

L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2000 ACS

AN 1991:137413 CAPLUS

DN 114:137413

TI Cloning of gene for human **fibronectin** analogs, its recombinant manufacture, and pharmaceuticals contg. same

IN Vogel, Tikva; Levanon, Avigdor; Werber, Moshe; Guy, Rachel; Panet, Amos

PA Bio-Technology General Corp., USA

SO PCT Int. Appl., 295 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 9007577	A1	19900712	WO 1989-US5875	19891229
	W: AU, DK, FI, JP, KR, NL				
	RW: AT, BE, CH, DE, ES, FR, GB, IT, LU, NL, SE				
	CA 2006929	AA	19900629	CA 1989-2006929	19891229
	AU 9049598	A1	19900801	AU 1990-49598	19891229
	AU 636596	B2	19930506		
	EP 451211	A1	19911016	EP 1990-902086	19891229
	R: AT, BE, CH, DE, ES, FR, GB, IT, LI, LU, NL, SE				
	JP 04505698	T2	19921008	JP 1990-502804	19891229
	JP 3095771	B2	20001010		
	DK 9101280	A	19910829	DK 1991-1280	19910628
	US 5455158	A	19951003	US 1993-58241	19930504
	US 5679320	A	19971021	US 1994-259569	19940614
	US 5965383	A	19991012	US 1995-409750	19950324
	US 5869616	A	19990209	US 1997-826885	19970408
	US 6121426	A	20000919	US 1997-909140	19970811

PRAI US 1988-291951 19881229

US 1989-345952 19890428

CA 1989-2006929 19891229

WO 1989-US5875 19891229

US 1990-526397 19900521

US 1991-703842 19910521

US 1993-58241 19930504

US 1994-259569 19940614

US 1995-409750 19950324

TI Cloning of gene for human **fibronectin** analogs, its recombinant manufacture, and pharmaceuticals contg. same

AB **Fibronectin** fragments contg. the cell-binding domain or the

**fibrin-binding domain** for use inter alia as

platelet-aggregation inhibitors, in wound healing and in the prevention

of

iatrogenic infections are manufd. by expression of a cDNA encoding the domain in Escherichia coli. These fragments are not necessarily the same as those derived by proteolysis of **fibronectin**. A

**fibronectin** cDNA was cloned from a human liver cDNA bank in .lambda.gt11 using oligonucleotides probes for regions of the **N-terminal** and cell-binding domains. After recovery of the complete sequence the regions encoding individual domains were subcloned and expressed in *E. coli*. In platelet aggregation inhibition assays a 40 kilodalton cell-binding domain inhibited aggregation 40% at 0.5 .mu.M.

In the same assay the pentapeptide GRGDS was as effective at 25 .mu.M. The 31 kilodalton **fibrin-binding domain** was shown to bind to *Staphylococcus aureus* as effectively as the comparable proteolytic fragment.

ST **fibronectin** cDNA cloning expression *Escherichia*; platelet aggregation inhibitor recombinant **fibronectin**; wound healing recombinant **fibronectin** fragment; bacterial colonization inhibitor recombinant **fibronectin**; catheter coating recombinant **fibronectin** fragment

IT Gene and Genetic element, animal  
 RL: BIOL (Biological study)  
 (cDNA, for **fibronectin** of cell- and **fibrin**-binding domains, of human, cloning and expression in *Escherichia coli* of,)

IT Fibronectins  
 RL: BIOL (Biological study)  
 (cell- and **fibrin**-binding domains of, for therapeutic uses, recombinant manuf. of, cloning of **fibronectin** cDNA in *Escherichia coli* in relation to)

IT *Escherichia coli*  
 (cloning and expression in, of **fibronectin** cell- and **fibrin-binding domain** cDNAs, of human)

IT Blood-coagulation factors  
 Interferons  
 RL: BIOL (Biological study)  
 (conjugates with **fibronectin** domain peptides, pharmaceutical uses of)

IT Neoplasm  
**Thrombus** and Blood clot  
 (detection of, **fibronectin** domains for, recombinant manuf. of)

IT Wound healing  
 (**fibronectin** derivs. for treatment of, recombinant manuf. of)

IT Fibrins  
 RL: BIOL (Biological study)  
 (**fibronectin** domain binding, analogs of, recombinant manuf. of)

IT Fermentation  
 (**fibronectin** domain-contg. polypeptides, with recombinant *Escherichia coli*)

IT Blood platelet aggregation inhibitors  
 (**fibronectin** domains as, recombinant manuf. of)

IT Bacteria  
*Staphylococcus aureus*  
 (**fibronectin** domains binding to, 31,000 mol.-wt., recombinant manuf. of)

IT Thrombolytics  
 (**fibronectin** domains conjugated fibrinolytic enzymes as)

IT Extracellular matrix  
 (**fibronectin fibrin-binding domain** binding to)

IT Burn  
 (healing of, stimulation of, **fibronectin** domains for, recombinant manuf. of)

IT Molecular cloning  
 (of **fibronectin** cDNA, of human, in *Escherichia coli*)

IT Drug bioavailability  
 (of **fibronectin** domain peptides, of human, in rats)

IT Thromboxanes  
 RL: BIOL (Biological study)

(release from platelets of, inhibition of, **fibronectin** derivs. for)

IT Eye, disease or disorder  
Tendon  
(wounding of, healing of, stimulation of, **fibronectin** domains for, recombinant manuf. of)

IT Heart, disease or disorder  
(angina pectoris, **fibronectin** derivs. for treatment of, recombinant manuf. of)

IT Artery, disease or disorder  
(angioplasty, recovery from, platelet aggregation inhibition in, **fibronectin** domains and conjugates for)

IT Animal growth regulators  
RL: BIOL (Biological study)  
(blood platelet-derived growth factors, conjugates with **fibronectin** domain peptides, pharmaceutical uses of)

IT Medical goods  
(catheters, as route for infection, **fibronectin** domains as coating for prevention of)

IT Brain, disease or disorder  
(cerebrovascular, treatment of, use of **fibronectin** domains as platelet-aggregation inhibitors in)

IT Albumins, compounds  
RL: BIOL (Biological study)  
(conjugates, with **fibronectin** domain peptides, pharmaceutical uses of)

IT Eye, disease or disorder  
(cornea, epithelium, wounding of, healing of, stimulation of, **fibronectin** domains for, recombinant manuf. of)

IT Eye, disease or disorder  
(cornea, stroma, wounding of, healing of, stimulation of, **fibronectin** domains for, recombinant manuf. of)

IT Cardiovascular system  
(disease, **fibronectin** derivs. for treatment of, recombinant manuf. of)

IT Circulation  
(extracorporeal, cardiopulmonary bypass, recovery from, platelet aggregation inhibition in, **fibronectin** domains and conjugates for)

IT Animal growth regulators  
RL: BIOL (Biological study)  
(fibroblast-derived growth factors, conjugates with **fibronectin** domain peptides, pharmaceutical uses of)

IT Deoxyribonucleic acid sequences  
(**fibronectin**-specifying, of human, complete)

IT Heart, disease or disorder  
(infarction, acute, **fibronectin** derivs. for treatment of, recombinant manuf. of)

IT Lymphokines and Cytokines  
RL: BIOL (Biological study)  
(interleukins, conjugates with **fibronectin** domain peptides, pharmaceutical uses of)

IT Plasmid and Episome  
(pFN126-3, gene for human **fibronectin** domain on, expression in *Escherichia coli* of)

IT Plasmid and Episome  
(pFN132-5, gene for human **fibronectin** domain on, expression in *Escherichia coli* of)

IT Plasmid and Episome  
(pFN137-2, gene for human **fibronectin** domain on, expression in *Escherichia coli* of)

IT Plasmid and Episome  
(pFN949-2, gene for human **fibronectin** domain on, expression in *Escherichia coli* of)

IT Plasmid and Episome  
(pFN975-25, gene for human **fibronectin** domain on, expression

in Escherichia coli of)

IT Skin, disease or disorder  
(transplant, healing of, stimulation of, **fibronectin** domains  
for, recombinant manuf. of)

IT Lymphokines and Cytokines  
RL: BIOL (Biological study)  
(tumor necrosis factor, conjugates with **fibronectin** domain  
peptides, pharmaceutical uses of)

IT Animal growth regulators  
RL: BIOL (Biological study)  
(.alpha.-transforming growth factors, conjugates with  
**fibronectin** domain peptides, pharmaceutical uses of)

IT Animal growth regulators  
RL: BIOL (Biological study)  
(.beta.-transforming growth factors, conjugates with  
**fibronectin** domain peptides, pharmaceutical uses of)

IT 9002-01-1D, Streptokinase, conjugates with **fibronectin** domain  
peptides 9039-53-6D, Urokinase, conjugates with **fibronectin**  
domain peptides 81669-57-0D, Eminase, conjugates with  
**fibronectin** domain peptides 82657-92-9D, Prourokinase,  
conjugates with **fibronectin** domain peptides  
RL: PRP (Properties)  
(as thrombolytic)

IT 80146-85-6, Transglutaminase  
RL: PRP (Properties)  
(binding of **fibronectin** domain polypeptides to **fibrin**  
stimulation by)

IT 9001-27-8D, Blood-coagulation factor VIII, conjugates with  
**fibronectin** domain peptides 9013-56-3D, Blood-coagulation factor  
XIII, conjugates with **fibronectin** domain peptides 9054-89-1D,  
Superoxide dismutase, conjugates with **fibronectin** domain  
peptides 11096-26-7D, Erythropoietin, conjugates with  
**fibronectin** domain peptides 25322-68-3D, conjugates with  
**fibronectin** domain peptides 62229-50-9D, Epidermal growth  
factor, conjugates with **fibronectin** domain peptides  
62683-29-8D, Colony-stimulating factor, conjugates with  
**fibronectin** domain peptides 81627-83-0D, Colony-stimulating  
factor 1, conjugates with **fibronectin** domain peptides  
83869-56-1D, Colony-stimulating factor 2, conjugates with  
**fibronectin** domain peptides  
RL: PRP (Properties)  
(pharmaceutical uses of)

IT 57576-52-0, Thromboxane A2  
RL: PRP (Properties)  
(release from platelets of, inhibition of, **fibronectin**  
derivs. for)

IT 105913-11-9D, Plasminogen activator, conjugates with **fibronectin**  
domain peptides  
RL: PRP (Properties)  
(tissue-type, as thrombolytic)

=> File biosis, embase, medline, scisearch, lifesci, caplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	55.95	56.25
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.18	-1.18

FILE 'BIOSIS' ENTERED AT 18:26:10 ON 31 DEC 2000  
COPYRIGHT (C) 2000 BIOSIS(R)

FILE 'EMBASE' ENTERED AT 18:26:10 ON 31 DEC 2000

COPYRIGHT (C) 2000 Elsevier Science B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 18:26:10 ON 31 DEC 2000

FILE 'SCISEARCH' ENTERED AT 18:26:10 ON 31 DEC 2000

COPYRIGHT (C) 2000 Institute for Scientific Information (ISI) (R)

FILE 'LIFESCI' ENTERED AT 18:26:10 ON 31 DEC 2000

COPYRIGHT (C) 2000 Cambridge Scientific Abstracts (CSA)

FILE 'CAPLUS' ENTERED AT 18:26:10 ON 31 DEC 2000

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

=> s fibronectin

L8 96041 FIBRONECTIN

=> s fibrin

L9 84300 FIBRIN

=> s L9 and (N-terminal fibrin binding domain)

L10 17 L9 AND (N-TERMINAL FIBRIN BINDING DOMAIN)

=> s L9 and (marker or image or isotope or label)

L11 1917 L9 AND (MARKER OR IMAGE OR ISOTOPE OR LABEL)

=> dup rem L11

PROCESSING IS APPROXIMATELY 46% COMPLETE FOR L11

PROCESSING IS APPROXIMATELY 84% COMPLETE FOR L11

PROCESSING COMPLETED FOR L11

L12 927 DUP REM L11 (990 DUPLICATES REMOVED)

=> L12 and (thrombus or atherosclerotic plaque)

L12 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter

"HELP COMMANDS" at an arrow prompt (=>).

=> s L12 and (thrombus or atherosclerotic plaque)

L13 116 L12 AND (THROMBUS OR ATHEROSCLEROTIC PLAQUE)

=> s L12 and (N-terminal fibrin binding domain)

L14 0 L12 AND (N-TERMINAL FIBRIN BINDING DOMAIN)

=> s L10 and L13

L15 0 L10 AND L13

=> s L2 and L12

L16 0 L2 AND L12

=> s L2 and L13

L17 0 L2 AND L13